OBJECTIVE: To probe into the efficacy of Kangfuxin liquid in adjuvant anti-tuberculous chemotherapy for intestinal tuberculosis and its effects on inflammatory factors and T-lymphocyte subsets. METHODS: Totally 92 patients with intestinal tuberculosis admitted into this hospital from Feb. 2018 to Oct. 2019 were extracted to be randomly divided into the study group（ n = 46） and the control group（ n = 46）. The control group was given conventional basic treatment + 2 HRZE/4 HR anti-tuberculosis chemotherapy regimen

while the study group received Kangfuxin liquid on the basis of the control group. The clinical efficacy of two groups were compared

and the changes of levels of inflammatory factors [tumor necrosis factor-α（ TNF-α）

interleukin-1（ IL-1）

interleukin-10（ IL-10）

Creactive protein（ CRP） ] and T lymphocyte subsets（ CD3

+

CD4

+

CD8

+

CD4

+

/CD8

+

） before and after treatment were compared between two groups. Adverse drug reactions of two groups were compared. RESULTS: The total effective rate in the study group was 89. 13%（ 41/46）

significantly higher than 69. 57%（ 32/46） in the control group

the difference was statistically significant（ P

<

0. 05）. After treatment

the levels of TNF-α

IL-1

IL-10

CRP and CD8

+

in two groups were significantly lower than those before treatment

and the study group was significantly lower than the control group

with statistically significant differences（ P

<

0. 05）. After treatment

the levels of CD3

+

CD4

+

and CD4

+

/CD8

+

in two groups were significantly higher than those before treatment

and the study group was higher than the control group

the differences were statistically significant（ P

<

0. 05）. The incidence of total adverse drug reactions in the study group and the control group were respectively 32. 61%（ 15/46） and 28. 26%（ 13/46）

with statistically significant differences（ χ~2= 0. 205

P = 0. 650）. CONCLUSIONS: Kangfuxin liquid in adjuvant antituberculous chemotherapy for intestinal tuberculosis can significantly reduce the level of inflammatory factors

improve the cellular immune system

and enhance the clinical effects with higher safety.